Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q2 2017 · 10-Q
Revenue$12.27M$12.27M+83.5% vs Q2 2016 Net Income-$3.28M-$3.28MN/M vs Q2 2016 EPS Diluted-$0.26-$0.26N/M vs Q2 2016 Gross Profit$2,332,791+53.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Operating Cash Flowderived-$863,056N/M Margins · derivedGross margin19.0%−3.7 pt vs Q2 2016
Operating margin-28.6%−14.6 pt vs Q2 2016
Net margin-26.7%−8.6 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 14, 2017 · 45 d after period end